# PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029

**Minutes of Pre-bid Meeting dated 23/11/2026**

**Section I: Top Sheet**

| | | | |
|---|---|---|---|
| **File No:** | PMBI/07/83/PROC/2026 | **Date:** | 12/11/2026 |
| **Description** | e-Tender no. PMBI/DRUG/RC-242/2026 for the supply of 203 nos. of Drugs/ Medicines to Pharmaceuticals & Medical Devices Bureau of India (PMBI) for two years. | **Estimated Cost: -** | 941.24 crores approx. |
| **Tender Published In** | CPP-portal & PMBI website | **Date of Publication** | 14/11/2026 |
| **Bid Validity** | 150 days | **Bid Opening Date** | 11/12/2026 |
| **Advertisement of the tender** | The Tender has been advertised through widely circulated News-papers viz ***Amar Ujala*** *(Dehradun & Delhi)****, Andhra Jyothi, Dainik Bhaskar*** *(Indore & Ludhiana)****, Dinakaran (****Chennai)****, Divya Himachal*** *(Shimla)****, Hindustan Times*** *(Delhi, Jalandhar & Lucknow)****, Loksatta*** *(Mumbai & Pune)****, Summit Times (****Sikkim)****, Tribune*** *(Chandigarh & Gurgaon)* | | |

**Section II:**

**PMBI officials attended the meeting:**

| Sr. No. | Name | Designation | Tender Committee (TC) |
|---|---|---|---|
| 1 | Ms. N.J. Sujatha | Deputy Chief Executive Officer | Chairperson/ Member |
| 2 | Sh. Ravikant Tiwari | General Manager (Finance & Accounts) | Member |
| 3 | Sh. Sanjay Kumar | External Expert | Member |
| 4 | Sh. Rinku Giri | Manager (Sales & Marketing) | Member |
| 5 | Sh. Prateek Mishra | Manager (Sales and Marketing and Procurement) | Member |
| 6 | Sh. Sanjay Lohani | Manager (Logistics & Supply chain) | Member |
| 7 | Sh. Rishabh Nagar | Deputy Manager (Procurement) | To present tender to Tender Committee |

**Attendees of the Pre-bid Meeting (Hybrid mode) -** Representatives of the following manufacturers have physically attended the pre-bid meeting:

1. Elnova Pharma
2. Fertin India Pvt. Ltd.
3. IPCA Laboratories Ltd.
4. Mascot Health Series Pvt. Ltd.
5. Ravian Life Science Pvt. Ltd.
6. Ronam Healthcare Pvt. Ltd.
7. Torque Pharmaceuticals Pvt. Ltd.
8. Zim Laboratories Ltd.

**Section III: Deliberation on Salient Features of the Tender:**

At the beginning of the meeting, the Tender Committee (TC), greeted the delegates of the potential bidders and briefed them about the key terms & conditions of the tender document highlighting the revised tender clause related to the submission of Certificate of Pharmaceutical Product (CoPP) for each such product for which the bidder is awarded along with the agreement after issuance of LoA.
Moreover, the Committee has provided a detailed interpretation of the sections related to the Performance

Security Deposits (PSD) whereby the successful bidder is required to give an irrevocable Bank Guarantee (BG) equivalent to 3% of the value of the Purchase Order (PO) within 10 days, having at least 36 months validity from the date of PO. The BG shall be submitted as per the given format in Annexure XXIII along with the agreement and will be released within 60 days after fulfillment of all the contractual obligations, including shelf-life obligations.

Furthermore, the Committee also clarified on the time period for deliveries, which is 45 days for the supply under the first PO and 30 days thereafter for all the subsequent POs except injectables, infusions and vials i.e. products that do not require sterility testing.

Lastly, with regards to the bid price (rate per tablet/capsule), the Committee has told the bidders to quote their rate as per the unit size specified in Annexures XII and XIII and Bill of Quantity (BOQ) and strictly informed that price bid shall only be uploaded under Cover-B in the specified template on CPP portal without disclosing them under technical bid (Cover-A).

**Section IV: Queries of the intending bidders discussed during the pre-bid meeting**

Pre-bid meeting against the subject tender was scheduled on 23/11/2026 from 11:00 hours onwards. The meeting was scheduled to be convened in physical mode at Conference Hall, PMBI as well as in hybrid mode whereas participant requested to provide link to join the meeting through video conference mode and it was provided to the intending bidders based on their request as per tender provisions.

PMBI has received queries from manufacturers through email prior to the pre-bid meeting whereas total 08 representative have attended the pre-bid meeting and 01 participants have also joined the meeting through video conference mode.

Later, the prospective bidders were requested to offer their views/ suggestions/ queries one by one regarding the terms & conditions and other details of the e-tender document followed by the other detailed discussion on the submitted queries.

Regarding terms and conditions/ detailed or packaging specifications, the representatives have offered their views/ suggestions/ queries and the same is discussed hereunder in the table:

| S. No. | Manufacturer Name (M/s) | Query/ Suggestions of the representatives | PMBI Clarification |
|---|---|---|---|
| 1. | Fertin India Pvt. Ltd. | Representative of the manufacturer has requested to consider their annual turnover as they are collaborating with foreign-registered companies, proposing that the combined financial strength and credentials of both entities may be considered to meet the tender eligibility criteria. | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |
| 2. | IPCA Laboratories Ltd | Representative of the manufacturer has requested to amend the following:<br>a. Bidder has requested to amend the generic name and detailed specification of DC-489 – Sulfasalazine Gastro-Resistant Tablets 1000 mg from Gastro resistant tablet to enteric-coated tablet<br>b. Bidder has requested to amend the detailed specification DC-999 – Paroxetine Prolonged-Release Tablets IP 37.5 mg from enteric-coated prolonged-release tablets to film coated prolonged-release.<br>c. Bidder seeks information regarding DC-2830, DC-2832 & DC-2833 Methylphenidate Tablets:<br>Since Methylphenidate is a Schedule X (NRx) drug, they have requested clarification on whether the designated warehouse holds the requisite license and statutory permissions for storage and handling of these medicines. | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |
| 3. | Mascot Health Series Pvt. Ltd | Representative of the manufacturer has requested to amend the following:<br>a. Bidder has requested to amend the detailed specification of DC-510 from Film-coated tablet to Uncoated tablet.<br>b. Bidder has requested to amend the Generic Name & detailed specification of DC-835 as Glucosamine Sulphate as Potassium Chloride instead of Sodium | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |

| | | | |
|---|---|---|---|
| | | Chloride IP.<br>c. Bidder has requested to amend the detailed specification of DC-482 as Rabeprazole as enteric-coated pellets and Levosulpiride as sustained-release pellets in a hard gelatin capsule instead of Rabeprazole Sodium IP 20mg (as Gastro-resistant pellets) Levosulpiride 75mg (as sustained release Tablet).<br>**Clause 21(P), Package Inserts:** They have requested to accept/ include the complete product information with insert in final packaging through Quick Response code (QR code) printed on the secondary packaging/carton, linking to complete product information instead of physical (paper) insert. | |
| 4. | Ravian Life Science Pvt. Ltd. | Representative of the manufacturer has requested to consider the following:<br>a. **Performance Security Deposit (PBG):** Request to allow consolidated PBG submission either on a six-monthly basis or against the LOA instead of PO-wise submission.<br>b. **PBG Percentage and Validity:** Request to consider 5% PBG instead of the existing 3%, with submission against LOA or on a six-monthly basis and validity of 2–3 years, as applicable.<br>c. **Film-coated Tablets:** Request to amend the detailed specification of film-coated tablets as an alternative to specified uncoated tablets, subject to compliance with applicable quality and technical standards.<br>d. **Repeated Document Submission:** Request to avoid repeated submission of documents already uploaded and verified on the Vendor Registration Portal.<br>e. Bidder has requested to amend the detailed specification of DC-124 Povidone Iodine Ointment 5% w/w to accept products complying with USP Monograph instead of IP Monograph. | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |
| 5. | Ronam Healthcare Pvt. Ltd. | Representative of the bidder has requested to amend the detailed specification of DC-320: Diazepam Tablets IP 5mg as each uncoated tablet instead of film-coated tablet. | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |
| 6. | Serum Institute of India Pvt. Ltd. | Representative of the manufacturer has requested to amend the following:<br>a. Amend the packaging type and unit size of DC-2819 from 0.5 ml pre-filled syringe (PFS) to 0.5 ml vial in monocarton.<br>b. **Delivery Schedule, Clause 19(H):** Requested to extend the delivery period to 120 days for biological products and 180 days for vaccines, mentioning the required time period for in-house testing and sterility testing.<br>c. **PMBJP Logo on Small Vials, Enclosure-2, Annexure-VII (2):** Request to permit printing of the PMBJP logo and drug code on secondary and tertiary packaging instead of directly on ampoules/vials below 5 ml.<br>**Tertiary Label Barcodes, GS1 Standards**: Request to allow the first GS1-128 format barcode to contain only GTIN, expiry date and batch number, with manufacturing date and quantity printed separately on the label. | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |
| 7. | Torque Pharmaceuticals Pvt. Ltd. | Representative of the manufacturer has requested to relax the stipulated delivery period for all drugs except Injectable/ Infusion/ Vials (Products do not required | The Tender Committee has mentioned to check the Amendment (if any) in this |

| | | | |
|---|---|---|---|
| | | sterility testing) from **45 to 60 days from the date of issuance of the first Purchase Order (PO).** | regard. |
| 8. | Zim Laboratories Ltd. | Representative of the manufacturer has requested to amend the following:<br>a. **Minimum Batch Size in L1 Rate Contract:** they have requested that the minimum batch size/ quantity be clearly specified and incorporated into the L1 rate contract to ensure clarity regarding order placement and supply requirements.<br>**Contact Details of Concerned Departments:** Since the vendor contact number provided is currently inactive, they have requested to share the contact details of the concerned officials from the **Procurement, Quality and Logistic Departments for relevant correspondence to PMBI.** | The Tender Committee has mentioned to check the Amendment (if any) in this regard. |

In response of the requests/ required clarifications from representatives, the Chairman, Tender Committee, PMBI clarified that necessary clarification/ amendment (if required) will be published after due scrutiny by the Tender Committee.

The chair concluded the meeting with vote of thanks.

Sd/-
Chief Executive Officer,
Pharmaceuticals & Medical Devices Bureau of India